TRE-515

TRE-515 is a first-in-class, orally administered small molecule inhibitor of deoxycytidine kinase (dCK), the rate-limiting enzyme in the nucleoside salvage pathway. By inhibiting dCK, TRE-515 halts nucleotide synthesis and prevents the metabolism of DNA precursors in tumor cells, thereby inhibiting DNA replication and potentially blocking tumor progression[1][2][4]. It is being developed for solid tumors and has shown promise in preclinical studies for autoimmune diseases such as multiple sclerosis, optic neuritis, systemic lupus erythematosus, and Crohn’s disease. TRE-515 has also been used experimentally under FDA Expanded Access for amyotrophic lateral sclerosis (ALS), where it demonstrated disease stabilization and improved patient outcomes with a favorable safety profile[2][8][9].

Other names

TRE 515TRE515TRE-515DI 87DI87DI-87